Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy

Launched by XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · Jul 21, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring how two medications, lacosamide and levetiracetam, can improve thinking and memory in patients with Alzheimer's disease who also have epilepsy. The study involves participants who have been diagnosed with Alzheimer's and are currently taking certain medications for their condition. Over six months, participants will be divided into two groups, with one group receiving lacosamide and the other receiving levetiracetam. Researchers will use various tests to measure any changes in cognitive function, which includes thinking skills and memory.

To be eligible for this trial, participants should be between the ages of 65 and 74, have a certain level of cognitive ability, and must be experiencing new seizures. They also need to agree to participate by signing a consent form. However, individuals with certain serious health issues or specific types of brain problems will not be included. This trial is currently recruiting participants, and it could be a valuable opportunity for those looking to help improve treatments for Alzheimer's disease and epilepsy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinically diagnosed as Alzheimer's disease and treated with cholinesterase inhibitors;
• • New seizures or subclinical epileptic discharges;
• • Mini-Mental State Examination score ≥ 18 points, and/or Clinical Dementia Rating (CDR) score \< 2 points;
• • Sign the informed consent form.
• Exclusion Criteria:
• • Suffering from syncope, transient ischemic attack, hysteria attack, migraine and other transient brain dysfunction;
• • Serious medical disease (especially atrioventricular block) or mental illness;
• • There are structural abnormalities related to epilepsy in other brain regions of imaging